Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyr6 (N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide)是选择性的 TRPC3抑制剂,IC50值为0.49uM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 363 | 现货 | ||
2 mg | ¥ 532 | 现货 | ||
5 mg | ¥ 889 | 现货 | ||
10 mg | ¥ 1,390 | 现货 | ||
25 mg | ¥ 2,470 | 现货 | ||
50 mg | ¥ 3,650 | 现货 | ||
100 mg | ¥ 5,180 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 968 | 现货 |
产品描述 | Pyr6 (N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide) is a selective TRPC3 inhibitor with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).Pyr6 is an inhibitor of Ca2+ entry, which displays higher potency to inhibit Ca2+ entry mediated by CRAC channel than by TRPC3. |
靶点活性 | TRPC3:0.49 uM |
体外活性 |
Pyr3 is selective inhibitor of TRPC3, inhibited Orai1- and TRPC3-mediated Ca(2+) entry and currents as well as mast cell activation with similar potency.?By contrast, Pyr6 exhibited a 37-fold higher potency to inhibit Orai1-mediated Ca(2+) entry as compared with TRPC3-mediated Ca(2+) entry and potently suppressed mast cell activation. |
别名 | N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide |
分子量 | 418.27 |
分子式 | C17H9F7N4O |
CAS No. | 245747-08-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (227.12 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3908 mL | 11.954 mL | 23.908 mL | 59.77 mL |
5 mM | 0.4782 mL | 2.3908 mL | 4.7816 mL | 11.954 mL | |
10 mM | 0.2391 mL | 1.1954 mL | 2.3908 mL | 5.977 mL | |
20 mM | 0.1195 mL | 0.5977 mL | 1.1954 mL | 2.9885 mL | |
50 mM | 0.0478 mL | 0.2391 mL | 0.4782 mL | 1.1954 mL | |
100 mM | 0.0239 mL | 0.1195 mL | 0.2391 mL | 0.5977 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pyr6 245747-08-4 Membrane transporter/Ion channel TRP/TRPV Channel N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide Inhibitor TRP Channel inhibit Pyr 6 Pyr-6 Transient receptor potential channels inhibitor